NVO - Novo Nordisk A/S
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 64.34 |
| Open | 65.00 |
| Bid | 64.00 x 900 |
| Ask | 64.33 x 1000 |
| Day's Range | 64.01 - 65.00 |
| 52 Week Range | 47.25 - 66.10 |
| Volume | 878,168 |
| Avg. Volume | 2,178,492 |
| Market Cap | 151.434B |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | 26.19 |
| EPS (TTM) | 2.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.57 (2.43%) |
| Ex-Dividend Date | Mar 27, 2020 |
| 1y Target Est | 70.72 |
- Zacks
The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global
The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global
- Zacks
Top Stock Reports for Novo Nordisk, IBM & Honeywell
Top Stock Reports for Novo Nordisk, IBM & Honeywell
- MarketWatch
White House announces plan for Medicare enrollees to get insulin for $35 a month
Medicare recipients will be able to get prescription plans that limit copays for insulin, a potential savings of hundreds of dollars, the White House announced Tuesday in a pivot to pocketbook issues that could influence November’s election.
- Zacks
Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY
Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.
- Simply Wall St.
Novo Nordisk A/S (CPH:NOVO B) Just Beat Earnings: Here's What Analysts Think Will Happen Next
A week ago, Novo Nordisk A/S (CPH:NOVO B) came out with a strong set of quarterly numbers that could potentially lead...
- Zacks
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.
- Motley Fool
Novo Nordisk A/S (NVO) Q1 2020 Earnings Call Transcript
Image source: The Motley Fool. Novo Nordisk A/SÂ (NYSE: NVO)Q1Â 2020 Earnings CallMay 6, 2020, 7:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorHello and welcome to the Q1 2020 Novo Nordisk AS Earnings Conference Call.
- Reuters
European shares flat as mixed earnings, U.S.-China tensions weigh
European shares opened little changed on Wednesday as a batch of mixed earnings reports and simmering U.S.-China tensions added to doubts about a swift economic recovery even as many countries eased lockdown measures. The pan-European STOXX 600 index was flat as losses in oil and gas sector, following a recent surge, offset gains in healthcare shares. The global mood also remained fragile as U.S. President Donald Trump again took aim at China, urging it to be transparent about the origins of the novel coronavirus outbreak.
- Simply Wall St.
Novo Nordisk (CPH:NOVO B) Could Easily Take On More Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- GuruFocus.com
5 Pharmaceutical Companies to Consider as Coronavirus Vaccine Race Heats Up
Biotech and drug manufacturing companies with the strength to weather further coronavirus storms Continue reading...
- PR Newswire
Novo Nordisk offers free 90-day insulin supply to people experiencing financial hardship due to COVID-19
People with diabetes using Novo Nordisk Inc. insulin who have lost health insurance coverage because of a change in job status due to the COVID-19 pandemic may now be eligible for enrollment in our Diabetes Patient Assistance Program (PAP) and receive insulin free of charge for 90 days.
- Reuters
Europe's coronavirus export bans raise concern over insulin supplies
Several European countries have banned the export of insulin in recent weeks, a move industry officials said was based on a misguided fear that the COVID-19 pandemic would cause shortages of a drug vital to millions of diabetes patients. EU curbs on drug exports during the coronavirus emergency mostly cover medication used to treat COVID-19, including muscle relaxants, painkillers and hydroxychloroquine.
- Reuters
Eli Lilly lowers insulin costs as coronavirus crisis deepens
Drugmaker Eli Lilly & Co said on Tuesday it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom are facing financial difficulties due to the coronavirus outbreak. The new co-pay scheme covers most of Lilly's insulins, including widely-used Humalog injection, and can be availed by people with commercial insurance as well as those without insurance. "Enabling a $35-per-month insulin co-pay regardless of employment status will help many Americans in this difficult time," said CEOs Aaron Kowalski and Thom Scher of non-profit organization JDRF-Beyond Type 1 Alliance.
- GuruFocus.com
Alnylam, Dicerna Join Forces to Take on Arrowhead
Companies in race to find treatment for genetic disease that can cause lung and liver disease Continue reading...
- Insider Monkey
Highlights From Fundsmith Equity Fund ‘s 2020 Investor Letter
On March 31, Fundsmith Equity Fund published an investor letter in which it has reported how the fund is faring in the coronavirus Covid-19 pandemic environment. The Fundsmith Equity Fund continues to operate and the fund has been able to provide liquidity where required. According to their management, "Fund’s performance has been as they would […]
- PR Newswire
Coronavirus (COVID-19) resources available from Novo Nordisk in the US
We recognize that people with chronic diseases, including diabetes, obesity and hemophilia, are at increased risk during this pandemic and Novo Nordisk is taking measures to support the communities we serve throughout the COVID-19 pandemic.
- Investopedia
The Top 10 Biotechnology Companies
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more.
- Simply Wall St.
Novo Nordisk A/S (CPH:NOVO B) Pays A ø5.35 Dividend In Just 3 Days
Novo Nordisk A/S (CPH:NOVO B) stock is about to trade ex-dividend in 3 days time. You will need to purchase shares...
- GuruFocus.com
5 Dividend Growth Stocks Hedge Fund Gurus Own
Ford suspends dividend payments as coronavirus outbreak cripples plant operations Continue reading...
- Insider Monkey
Were Hedge Funds Right About Buying Novo Nordisk A/S (NVO)?
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- Reuters
US govt aims at high insulin prices with plan for $35 copay in Medicare
The Trump administration on Wednesday turned back to its pledge to fight high U.S. drug prices with a plan to limit the out-of-pocket cost for insulin, a life-saving medicine, to $35 per month for many people with diabetes who are enrolled in Medicare. The Center for Medicare and Medicaid Services, part of the U.S. Department of Health and Human Services, is lining up drug makers and the private insurers who manage Medicare drug benefits to volunteer to test out the new pricing in 2021. Medicare drug plans cover about 46 million people aged 65 and older and with disabilities.
- Simply Wall St.
If You Had Bought Novo Nordisk (CPH:NOVO B) Shares Three Years Ago You'd Have Made 68%
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
- GuruFocus.com
A Trio of Stocks Growing Earnings Fast
Novo Nordisk A/S tops the list Continue reading...
- Yahoo Finance
Oscar Health unveils program for lower drug prices, including insulin
Oscar Health is offering prescription drugs at rock-bottom prices, following the lead of other health care players responding to the public’s demand for lower costs.
- Zacks
SNY vs. NVO: Which Stock Should Value Investors Buy Now?
SNY vs. NVO: Which Stock Is the Better Value Option?
